SIRT4 inhibits B‐cell lymphoma proliferation by inhibiting mitochondrial glutamine metabolism52; in addition to this, SIRT4 inhibits B‐cell lymphoma proliferation by inhibiting glutamine metabolism from suppressing the malignant biological behavior of thyroid cancer cells53; In conclusion, these findings suggest the potential of SIRT4 for tumor‐targeted therapeutic aspects, especially its potential to synergize with glutamine metabolism inhibitors for cancer treatment. The gene discussed is SIRT4; the disease is B-cell non-Hodgkin lymphoma.